Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EPS (Basic) (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed EPS (Basic) for 4 consecutive years, with -$0.08 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 14.29% to -$0.08 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.34 through Dec 2025, up 5.56% year-over-year, with the annual reading at -$0.34 for FY2025, 5.56% up from the prior year.
  • EPS (Basic) hit -$0.08 in Q4 2025 for Taysha Gene Therapies, up from -$0.09 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.92 in Q4 2023 to a low of -$1.32 in Q1 2022.
  • Historically, EPS (Basic) has averaged -$0.32 across 4 years, with a median of -$0.1 in 2024.
  • Biggest five-year swings in EPS (Basic): surged 192.93% in 2023 and later crashed 107.61% in 2024.
  • Year by year, EPS (Basic) stood at -$0.99 in 2022, then soared by 192.93% to $0.92 in 2023, then plummeted by 107.61% to -$0.07 in 2024, then dropped by 14.29% to -$0.08 in 2025.
  • Business Quant data shows EPS (Basic) for TSHA at -$0.08 in Q4 2025, -$0.09 in Q3 2025, and -$0.09 in Q2 2025.